CN1764466A - Application of Mango and its extracts in treating diabetes and improving its symptoms - Google Patents
Application of Mango and its extracts in treating diabetes and improving its symptoms Download PDFInfo
- Publication number
- CN1764466A CN1764466A CNA2003801102572A CN200380110257A CN1764466A CN 1764466 A CN1764466 A CN 1764466A CN A2003801102572 A CNA2003801102572 A CN A2003801102572A CN 200380110257 A CN200380110257 A CN 200380110257A CN 1764466 A CN1764466 A CN 1764466A
- Authority
- CN
- China
- Prior art keywords
- effect
- improving
- drinking
- symptoms
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
茳芒及其提取物在治疗糖尿病及改善其症状药物中的应用 技术领域 Application of awns and its extracts in treating diabetes and improving its symptoms Technical field
本发明属于中药的药物用途领域。 The invention belongs to the field of medicinal application of traditional Chinese medicines.
背景技术 Background technique
茳芒 (Cassia sophera Li皿.), 药用植物, 豆科苏木亚科决明属。 据《中药大辞典》中记载: "茳芒, 又称茳芒决明, 性平, 无毒, 味 甘滑。 具有除痰止渴, 令人不睡, 调中的功效。 又称其为解热药。 茳芒 叶的醇提物有松弛豚鼠小肠、支气管平滑肌的作用。"本发明中是指的是 茳芒子。 Cassia sophera (Cassia sophera Lipan.), a medicinal plant, belongs to the genus Cassia in the family Fabaceae. According to the "Dictionary of Traditional Chinese Medicine": "Jiangmang, also known as Jiangmang cassia, is flat in nature, non-toxic, and sweet and slippery. It has the effect of eliminating phlegm and quenching thirst, making people sleepless, and regulating the middle. It is also known as Antipyretic. The ethanol extract of the leaves of Miscanthus has the effect of relaxing the small intestine and bronchial smooth muscle of guinea pigs." In the present invention, it refers to the seed of Miscanthus.
发明内容 Contents of the invention
本发明的目的就是应用茳芒及其水提取物制备治疗糖尿病及改善其 症状的药物。 The object of the present invention is exactly to prepare the medicine for treating diabetes and improving its symptoms by applying the radishes and its water extract.
其水提物采用水提方法为: Its water extract adopts water extraction method to be:
1.煎煮法: 以水为溶媒, 加热煮沸提取有效成分, 一般须提取 2-4 次, 溶媒用量一般为茳芒量的 6- 20倍。 1. Decoction method: Use water as the solvent, heat and boil to extract the active ingredients, generally 2-4 times of extraction is required, and the amount of solvent is generally 6-20 times the amount of awns.
2.渗漉法: 为茳芒经冷浸泡或温浸泡后, 以适当温度的溶媒, 流经 茳芒, 以溶出茳芒之成分。 2. Percolation method: After cold soaking or warm soaking, a suitable temperature solvent is used to flow through the longan to dissolve the components of the longan.
3.浸渍法: 为大量溶媒冷浸泡或温浸泡茳芒, 待成分溶出平衡后, 直接放出提取液。 3. Immersion method: cold or warm soaking of awns in a large amount of solvent. After the ingredients are dissolved and balanced, the extract is released directly.
4.超声提取法: 为茳芒经浸泡后, 与溶媒一起置超声波中, 利用超 声波的效应, 使茳芒成分溶出。 、 4. Ultrasonic extraction method: After soaking the awns, put them in ultrasonic waves together with the solvent, and use the effect of ultrasonic waves to dissolve the components of awns. ,
1 1
更正页(细则第 91条) 5.微波提取法:将茳芒与溶媒一同置微波中,利用微波使分子极化, 而使其成分溶出。 Correction page (Rule 91) 5. Microwave extraction method: Put the awns and the solvent together in the microwave, use the microwave to polarize the molecules, and dissolve the components.
当本发明用于制备治疗糖尿病及改善其症状的药物时, 其口服或胃 肠夕卜给药, 均是安全的, 在口服情况下, 其可以任何常规形式给药, 如 散齐!]、 颗粒剂、 片剂、 胶囊剂、 丸剂、 溶液剂、 悬浮液、 糖浆、 口腔含 片、 舌下含片等; 当该药物肠胃外给药时, 可采取任何常规形式, 例如 注射剂 (如静脉内注射)、 软膏剂、 栓剂、 经皮给药、 吸入剂等。 When the present invention is used to prepare medicines for treating diabetes and improving its symptoms, it is safe to be administered orally or parenterally. In the case of oral administration, it can be administered in any conventional form, such as powder! ], granules, tablets, capsules, pills, solutions, suspensions, syrups, buccal tablets, sublingual tablets, etc.; when the drug is administered parenterally, it may take any conventional form, such as injection (such as Intravenous injection), ointment, suppository, transdermal administration, inhalation, etc.
本发明制备治疗糖尿病及改善其症状的药物是由茳芒子或其水提取 物与固体或液体的赋形剂一起构成的, 这里使用的固体或液体的赋形剂 在本领域是众所周知的, 下面举几个具体例子, 散剂是内服的粉末剂, 它的赋形剂有乳糖、 淀粉、 浆糊精、 碳酸钙、 合成或天然硫酸铝、 氧化 镁、 硬脂酸镁, 碳酸氢钠、 干燥酵母等; 溶液剂的赋形剂有水、 甘油、 丙二醇、 单糖浆、 乙醇、 乙二醇、 聚乙二醇、 山梨糖醇等; 软膏剂的赋 形剂可以使用脂油, 含水羊毛脂、 凡士林、 甘油、 蜂腊、 木腊、 液体石 腊、 树脂、 高级腊等组合成的疏水剂或亲水剂。 The medicament for treating diabetes and improving its symptoms prepared by the present invention is composed of Mangosteen fruit or its water extract and solid or liquid excipients. The solid or liquid excipients used here are well known in the art. Here are a few specific examples. The powder is a powder for oral administration. Its excipients include lactose, starch, paste dextrin, calcium carbonate, synthetic or natural aluminum sulfate, magnesium oxide, magnesium stearate, sodium bicarbonate, dry Yeast, etc.; the excipients of the solution include water, glycerin, propylene glycol, simple syrup, ethanol, ethylene glycol, polyethylene glycol, sorbitol, etc.; the excipients of the ointment can be fatty oil, hydrated lanolin, vaseline , Glycerin, beeswax, wood wax, liquid paraffin, resin, high-grade wax and other combinations of hydrophobic or hydrophilic agents.
有效物质的剂量可以根据服用方式, 病人的年龄和体重及病情严重 程度和其它类似的因素而改变,口服量为: 10.0-15.0mg/kg,每日二次服用: 注身寸 8.0-10.0mg/kg,每日一次。 The dose of the active substance can be changed according to the way of administration, the age and weight of the patient, the severity of the disease and other similar factors. The oral dose is: 10.0-15.0mg/kg, twice a day: 8.0-10.0mg per day /kg, once a day.
本发明药物具有较好的降低血糖、治疗糖尿病及其改善症状的效果。 具体实施方式 The medicine of the invention has better effects of lowering blood sugar, treating diabetes and improving symptoms. Detailed ways
以下通过试验例来进一步阐述应用本发明制备所述药物的有益效 果, 这些试验例包括了药效学试验和临床疗效观察试验。 The beneficial effects of applying the present invention to the preparation of the drug will be further illustrated below through test examples, which include pharmacodynamic tests and clinical curative effect observation tests.
2 2
更正页(细则第 91条) 试验例 1 茳芒提取物对 Wistar大鼠高血糖动物模型的影响 1.1试验材料 Correction page (Rule 91) Test Example 1 The effect of the extract of awns on the Wistar rat hyperglycemia animal model 1.1 Test materials
药品 茳芒提取物, 由吉林大学再生医学科学研究所新药研究室提 供, 批号: 20010708; 消渴丸由广州中药一厂生产, 批准文号: (1994) 第 11146号。 Drugs Mango extract, provided by the New Drug Research Office of the Institute of Regenerative Medicine Science, Jilin University, batch number: 20010708; Xiaoke Pills produced by Guangzhou No. 1 Traditional Chinese Medicine Factory, approval number: (1994) No. 11146.
动物 wistar大鼠, 雌雄各半, 体重 195g -240g, 由吉林大学实验动 物部提供,质量合格证号: 医动字第 10-5110号; 主要试剂和仪器 链脲霉素 STZ 美国 sigma化学公司出品, 批号: 89H0604 Animal Wistar rats, half male and half female, body weight 195g-240g, provided by the Experimental Animal Department of Jilin University, quality certificate number: Yidongzi No. 10-5110; main reagents and instruments Streptozotocin STZ produced by American Sigma Chemical Company , lot number: 89H0604
血糖试条 北京怡成生物电子技术有限公司出品。 Blood glucose test strips are produced by Beijing Yicheng Bioelectronic Technology Co., Ltd.
JPS-III型快速血糖测试仪 北京怡成生物电子技术有限公司出品。 JPS-III Rapid Blood Glucose Tester Produced by Beijing Yicheng Bioelectronic Technology Co., Ltd.
离心机 北京医用离心机厂, 型号: LDZ5— 2。 Centrifuge Beijing Medical Centrifuge Factory, model: LDZ5-2.
全自动生化仪 日本日立公司出品, 型号: 日立 7170A型。 Fully automatic biochemical analyzer produced by Hitachi, Japan, model: Hitachi 7170A.
1.2试验方法 1.2 Test method
试验条件与方法: Test conditions and methods:
自吉林大学动物部引入 Wistar大鼠后, 饲养于吉林大学基础医学院 动物室, 室温 22-25°C, 湿度 30-60%,饲料组成: 玉米面 39%、 豆饼面 25°/。、 麦糠面 14%、 高粱面 10%、 骨粉 2.5%、 鱼粉 5%、 酵母 3.5%、 添 加剂 1% 。 After the Wistar rats were introduced from the Animal Department of Jilin University, they were kept in the animal room of the Basic Medical College of Jilin University, with a room temperature of 22-25°C and a humidity of 30-60%. , wheat bran flour 14%, sorghum flour 10%, bone meal 2.5%, fish meal 5%, yeast 3.5%, additive 1%.
取茳芒提取物药粉配成 5.2%(g/v)、 2.6%(g/v), 1.3%(g/v)大、 中、 小 三个剂量的供试药液。 消渴丸配成浓度为 20%(g/v)供试药液。 Take awn extract powder and make three doses of 5.2% (g/v), 2.6% (g/v), 1.3% (g/v) large, medium and small doses of the test liquid. Xiaoke pills were made into a test drug solution with a concentration of 20% (g/v).
自吉林大学动物部引入 Wistar大鼠 110只,雌雄各半,在本室适应 1 周, 禁食不禁水 4小时后, 称体重、 测血糖、 作标记。 选择血糖值在正 110 Wistar rats, half male and half male, were introduced from the Department of Animals of Jilin University. They were acclimatized in this room for 1 week, and after fasting for 4 hours, they were weighed, blood sugar was measured, and marked. Choose blood sugar
3 3
更正页(细则第 91条) 常范围内、状态好的 100只雌雄各半的大鼠做实验, 从中留 10只作为正 常对照组, 将 90只 Wistar大鼠用链脲霉素 STZ按 0.054g/kg造模型, 链 脲霉素 STZ用 0.05mol/L枸椽酸溶液 PH 4.5配成 2.0%的溶液,现用现配。 大鼠禁食不禁水 16小时后, 按体重腹腔一次注入链脲霉素 STZ药液。 第 8天禁食不禁水 4小时后, 测血糖, 其中血糖值大于 lOmmol/L为模 型成立。 与正常对照组比较有显著性差异 P<0.001。 将 54只高血糖模型 动物, 随机分为五组, 每组 10〜11只, 雌雄各组均分。 分组为: 正常对 照组、 模型组、 消渴丸组 2.0g/kg, 相当于临床用量的 4倍; 茳芒提取物 大剂量组 0.62g/kg、 中剂量组 0.31g/kg、 小剂量组 0.15g/kg, 相当于临床 用量的 8、 4、 2倍。 Correction page (Rule 91) 100 male and female rats in normal range and in good condition were used as experiments, and 10 of them were left as the normal control group. 90 Wistar rats were modeled with streptozotocin STZ at 0.054g/kg. Streptozotocin Prime STZ is made into a 2.0% solution with 0.05mol/L citrate solution pH 4.5, and it is ready-to-use. After the rats were fasted for 16 hours, the streptozotocin STZ liquid was injected intraperitoneally once according to body weight. On the 8th day, after fasting for 4 hours without food and water, the blood sugar was measured, and the model was established if the blood sugar value was greater than 10 mmol/L. Compared with the normal control group, there was a significant difference P<0.001. The 54 hyperglycemia model animals were randomly divided into five groups, each with 10-11 animals, male and female in each group. Grouped into: normal control group, model group, Xiaoke Pill group 2.0g/kg, which is equivalent to 4 times the clinical dosage; high-dose awn extract group 0.62g/kg, medium-dose group 0.31g/kg, low-dose group 0.15g/kg, equivalent to 8, 4, 2 times of the clinical dosage.
模型组给水 10ml/kg, 各给药组均给予 10ml/kg供试药液。 每日上午 9时左右灌胃给药, 连续四周, 每周测血糖、 体重, 按新体重计算药量一 次。于给药第四周后处死动物, 取血测血常规、血液生化指标、血液流变 学和胰岛素含量,并取胰腺进行病理组织学检查。将各组所得结果以均值 ( )士标准差 (S)表示, 结果与模型组进行组间 t检验, 判断其显著性。 The model group was given 10ml/kg of water, and each administration group was given 10ml/kg of the test drug solution. Daily administration at around 9:00 a.m. for four consecutive weeks, blood sugar and body weight were measured every week, and the dosage was calculated once based on the new body weight. After the fourth week of administration, the animals were sacrificed, and blood was taken to measure blood routine, blood biochemical indicators, hemorheology and insulin content, and pancreas was taken for histopathological examination. The results obtained in each group are expressed as mean ( ) ± standard deviation (S), and the results and the model group are subjected to inter-group t-test to judge their significance.
1.3试验结果 1.3 Test results
1.3.1对血糖的影响 1.3.1 Effects on blood sugar
给药后第三周茳芒提取物大剂量组、 中剂量组与模型组比较血糖明 显下降, P<0.05。 第四周茳芒提取物大、 中剂量组和消渴丸组血糖值均 降低, 与模型组比较, 具有明显统计学意义 P<0.05, 见表 1。 In the third week after the administration, the blood sugar of the high-dose and medium-dose groups of the extracts of the longan mangosteen significantly decreased compared with the model group, P<0.05. In the fourth week, the blood sugar levels of the large and medium doses of the mango extract group and the Xiaoke Pill group were all reduced, compared with the model group, there was a significant statistical significance P<0.05, see Table 1.
4 4
更正页 (;细则第 91条) 动 1组剂 Correction Page (; Rule 91) move 1 dose
量别 S Quantity S
表 1 茳芒提取物对高血糖模型大鼠血糖值 (mmol/L)的影响( ΐ士 s) 正常对照组 ~~模型组 消渴丸组 大剂量组 中剂量组 小剂 ¾组 lOml/kg 2. Og/kg 0.62g/kg 0.31g/kg 0.15g/kg Table 1. The effect of the awn extract on the blood sugar level (mmol/L) of hyperglycemia model rats (1 ± s). 2. Og/kg 0.62g/kg 0.31g/kg 0.15g/kg
10 8 9 10 9 8 给药前 6.11 ±0.53 17.52±2.40 17.22±3.22 17.04±3.34 17.10±2.63 16.34±3.32 一周 6.19±0.50 17.15±2.23 16.84±3.06 15.54±3.23 15.10±2.36 15.72±3.15 二周 6.12±0.41 15.85±3.02 14.57 ±3.02 13.59±2.60 14.06±2.53 15.18±3.23 三周 6.22:t0.31 14.05±3.52 11.97±2.53 10.93±2.58* 10.71±2, 72* 13.05±3.26 四周 5.89:t0.46 13.80±4.16 9.38±2.83* 9.07±2.78* 9.45 ±1.98* 11.71±3.53 与模型组比较 ,*P〈0.05 10 8 9 10 9 8 8.11 ± 0.53 17.52 ± 2.40 17.22 ± 3.22 17.04 ± 3.34 17.10 ± 2.6.34 ± 3.32 A week 6.19 ± 0.50 17.84 ± 3.23 15.10 ± 2.36.5.5.5.5.5.5.5.5. 0.41 15.85 ± 3.02 14.57 ± 3.02 13.59 ± 2.60 14.06 ± 2.53 15.18 ± 3.23 Three weeks 6.22: T0.31 14.05 ± 3.52 11.97 ± 2.58* 10.71 ± 2, 72* 13.26 each 5.89. 4.16 9.38±2.83* 9.07±2.78* 9.45±1.98* 11.71±3.53 Compared with the model group, *P<0.05
试验伊 ί! 2 本发明药物治疗糖尿病患者的临床观察 Test Yi ί! 2 Clinical Observations of Drug Treatment of Diabetes Patients of the Present Invention
2.1—般资料 见表 2 表 2糖尿病患者饮用茳芒子后的情况 2.1—General Information See Table 2. Table 2 Diabetic patients after drinking mango seeds
5 5
更正页(细则第 91条) 2.2、 治疗结果 Correction page (Rule 91) 2.2. Treatment results
2.2.1本发明的降糖效果极显著 2.2.1 The hypoglycemic effect of the present invention is very significant
从表 2可明显看出, 这 25名糖尿病患者经 28天饮用, 除 2名患者 出现腹泻和周身不适以外, 其余都有较明显降糖效果, 服用后和服用前 比较血糖值平均降低 2.0mmol/L, 重症患者降低 14.1mmol/L。 经 t测验 分析, t值 =3.161, 在自由度 N=N-1=23-1=22时, p=0.01的 t=2.819, 所 以降糖效果极显著。 It can be clearly seen from Table 2 that after 28 days of drinking among the 25 diabetic patients, except for 2 patients who experienced diarrhea and general discomfort, the rest had obvious hypoglycemic effects. Compared with before taking, the average blood sugar level decreased by 2.0mmol /L, in critically ill patients decreased by 14.1mmol/L. After t test analysis, t value = 3.161, when the degree of freedom N = N-1 = 23-1 = 22, p = 0.01 t = 2.819, so the hypoglycemic effect is extremely significant.
2.2.2饮用时间越长, 效果越好 2.2.2 The longer the drinking time, the better the effect
2.2.2.1饮用一周显效情况如表 3 : 2.2.2.1 The marked effect of drinking for one week is shown in Table 3:
饮用一周降糖效果分析 Analysis of hypoglycemic effect of drinking for one week
6 6
更正页(细则第 91条) 根据表 3进行 1:测验, 其结果: t=1.962, 当自由度 N-l=22-l=21时, ρ=0·05的 t=2.080, p=0,10的 t=1.721, 所以饮用一周虽有效果但不显著。 2.2.2.2饮用二周效果分析如表 4: Correction page (Rule 91) Carry out 1: test according to Table 3, the result: t=1.962, when the degree of freedom N-l=22-l=21, t=2.080 for ρ=0·05, t=1.721 for p=0,10, so drink for a week It is effective but not significant. 2.2.2.2 The effect analysis of drinking for two weeks is shown in Table 4:
表 4 饮用二周降糖效果分析 Table 4 Analysis of hypoglycemic effect of drinking for two weeks
t测验结果, t=2.2637,当自由度 N=N-1=22-1=21时, p=0.05的 t=2.080, p=0.10的 t=2.831, 所以差异显著, 即效果明显。 The t test result, t=2.2637, when the degree of freedom N=N-1=22-1=21, t=2.080 for p=0.05, t=2.831 for p=0.10, so the difference is significant, that is, the effect is obvious.
2.2.2.3饮用三周效果分析如表 5: 2.2.2.3 Analysis of the effect of drinking for three weeks is shown in Table 5:
更正页 (;细则第 91条) 表 5 饮用三周降糖效果分析 Correction Page (; Rule 91) Table 5 Analysis of the hypoglycemic effect of drinking for three weeks
t测验结果, t=2.5043,当自由度 N=N-1=19-1=18时, p=0.05的 t=2.101 p=0.01的 t=2.878, 所以效果显著。 t test results, t=2.5043, when the degree of freedom N=N-1=19-1=18, p=0.05 t=2.101 p=0.01 t=2.878, so the effect is significant.
2.2.2.4 饮用四周效果分析如表 6: 2.2.2.4 The effect analysis of drinking for four weeks is shown in Table 6:
8 8
更正页(细则第 91条) 患者 (An) 饮用前 饮用一周后 d Correction page (Rule 91) Patient (An) Before drinking One week after drinking d
血糖值 (X) 血糖值 (χ2) (X— X ) d— 7 Blood sugar level (X) Blood sugar level (χ 2 ) (X— X ) d— 7
Al 11.0 6.7 4.3 2.566 6.584 Al 11.0 6.7 4.3 2.566 6.584
A2 15.8 12.3 3.5 1.766 3.118A2 15.8 12.3 3.5 1.766 3.118
A3 11.3 10.8 0.5 -1.234 1.522A3 11.3 10.8 0.5 -1.234 1.522
A4 9.7 8.8 0.9 -0.834 0.695A4 9.7 8.8 0.9 -0.834 0.695
A5 12.3 8.8 3.5 1.766 3.118A5 12.3 8.8 3.5 1.766 3.118
A6 7.9 7.0 0.9 -0.834 0.695A6 7.9 7.0 0.9 -0.834 0.695
A7 12.0 10.8 1.2 -0.534 0.285A7 12.0 10.8 1.2 -0.534 0.285
A8 7.2 7.5 -0.3 -2.034 4.137A8 7.2 7.5 -0.3 -2.034 4.137
A9 9.7 7.6 2.1 0.366 0.133A9 9.7 7.6 2.1 0.366 0.133
A10 5.9 6.7 -0.8 -2.534 6.421A10 5.9 6.7 -0.8 -2.534 6.421
All 10.2 9.8 0.4 -1.334 1.779All 10.2 9.8 0.4 -1.334 1.779
A12 6.8 6.3 0.5 -1.234 1.522A12 6.8 6.3 0.5 -1.234 1.522
A13 11.7 8.5 3.2 1.466 2.149A13 11.7 8.5 3.2 1.466 2.149
A14 8.9 5.9 3.0 1.266 1.602A14 8.9 5.9 3.0 1.266 1.602
A15 9.8 9.5 0.3 -1.434 2.056A15 9.8 9.5 0.3 -1.434 2.056
A16 7.2 6.5 0.7 -1.034 1.069A16 7.2 6.5 0.7 -1.034 1.069
A17 8.7 8.7 0 -1.734 3.006A17 8.7 8.7 0 -1.734 3.006
A18 10.8 10.2 0.6 -1.134 1.258A18 10.8 10.2 0.6 -1.134 1.258
A19 6.8 6.5 0.3 -1.434 1.602A19 6.8 6.5 0.3 -1.434 1.602
A20 8.9 8.8 0.1 -1.634 2.669A20 8.9 8.8 0.1 -1.634 2.669
A21 6.8 6.5 0.3 -1.434 1.602A21 6.8 6.5 0.3 -1.434 1.602
A22 8.4 7.8 0.6 -1.134 1.258A22 8.4 7.8 0.6 -1.134 1.258
A23 23.9 9.8 14.1 12.366 152.917 总和 231.7 (N=23 ) 186.8.1(N=23) 39.9 201.251 平均 10.07 "x 8.078 Έ( 1.734 A23 23.9 9.8 14.1 12.366 152.917 Sum 231.7 (N=23 ) 186.8.1(N=23) 39.9 201.251 Average 10.07 "x 8.078 Έ( 1.734
经 t测验结果, t=3.161,当自由度 N=N-1=22-1=22时, p=0.05的 t=2.074, p=0.01的 t=2.819, 所以效果极显著。 According to the t-test results, t=3.161, when the degree of freedom N=N-1=22-1=22, t=2.074 for p=0.05, t=2.819 for p=0.01, so the effect is extremely significant.
通过分析得出, 糖尿病患者饮用本发明, 饮用时间越长, 效果越明 显, 即饮用一周基本无效, 饮用两周显现降糖效果, 饮用三周降糖效果 显著, 饮用四周后降糖效果极显著。 Through the analysis, it is concluded that the longer the drinking time for diabetics drinking the present invention, the more obvious the effect is, that is, drinking for one week is basically ineffective, drinking for two weeks shows the hypoglycemic effect, drinking for three weeks has a significant hypoglycemic effect, and drinking for four weeks The hypoglycemic effect is extremely significant .
2.2.3患病年限与饮用效果分析 2.2.3 Years of illness and analysis of drinking effect
将表 1中 23名饮用本发明的糖尿病患者分成两组:患病 5年以上的 为一组, 患病 4年以下的为一组, 进行统计分析, 其结果- Divide the 23 diabetic patients who drink the present invention in Table 1 into two groups: those who have been sick for more than 5 years are a group, and those who have been sick for less than 4 years are a group. Statistical analysis is carried out, and the results are -
9 9
更正页(细则第 91条) .1、 患病 5年以上的效果分析如表 7 Correction Page (Rule 91) .1. The effect analysis of the disease for more than 5 years is shown in Table 7
表 7 患病 5年以上的饮用效果分析 Table 7 Analysis of drinking effect after illness for more than 5 years
t测验结果, t=1.782,当自由度 N=N—1=13— 1=12时, p=0.05的 t=2.197, p=0.01的 t=1.782, 所以效果并不显著。 t test results, t=1.782, when the degree of freedom N=N—1=13—1=12, t=2.197 for p=0.05, t=1.782 for p=0.01, so the effect is not significant.
2.2.3.2、 患病 4年以下的饮用效果分析如表 8 2.2.3.2. The analysis of the drinking effect after the illness for less than 4 years is shown in Table 8
表 8 患病 4年以下的饮用效果分析 Table 8 Analysis of drinking effect after illness for less than 4 years
t测验结果, t=2.966,当自由度 N=N_ 1=10—1=9时, p=0.05的 t=2.262, p=0.01的 t=3.250,所以效果显著。 t test results, t=2.966, when the degree of freedom N=N_ 1=10—1=9, t=2.262 for p=0.05, t=3.250 for p=0.01, so the effect is significant.
10 10
更正页(细则第 91条) 2.3结论 Correction page (Rule 91) 2.3 Conclusion
1、 茳芒子对糖尿病患者降血糖有显著效果。 1. Mango seed has a significant effect on lowering blood sugar in diabetic patients.
2、 糖尿病患者服用茳芒子两周即可显效, 四周效果显著。 2. Diabetic patients will be able to see the effect after taking Mangzi for two weeks, and the effect will be remarkable after four weeks.
3、 患病时间短 (4年以下) 比时间长 (5年以上) 服用茳芒子效果 好。 3. If the duration of illness is shorter (less than 4 years) than if the duration of illness is longer (over 5 years), the effect of taking mango seeds is better.
以下通过实施例来进一步阐述本发明药物的制备。 The preparation of the medicament of the present invention is further illustrated below by way of examples.
实施例 1 Example 1
茳芒子水提取物 2.0g,水 lOOOOml, 混合后装入 100 支瓶中, 每支 100ml, 含茳芒子提取物 20mg。 2.0g of water extract of Mango chinensis and 1000ml of water are mixed and put into 100 bottles, each 100ml contains 20mg of Mango mango extract.
实施例 2 Example 2
茳芒子 15.0g,药用淀粉 485g, 二者充分混合, 装胶囊, 制成 1000粒 胶囊, 每粒重 0.5g,含茳芒子 15mg。 15.0g of Longmanse and 485g of medicinal starch, the two are fully mixed, packed into capsules, and made into 1000 capsules, each weighing 0.5g, containing 15mg of Longmanse.
11 11
更正页(细则第 91条) Correction page (Rule 91)
Claims (1)
- Claims, cyperus awns preparing treatment diabetes and the application in improving the medicine of its symptom., cyperus awns water extract preparing treatment diabetes and the application in improving the medicine of its symptom12Correct page(The 91st article of detailed rules and regulations)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2003/000995 WO2005049057A1 (en) | 2003-11-24 | 2003-11-24 | Use of cassia sophera linn. for treating diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1764466A true CN1764466A (en) | 2006-04-26 |
Family
ID=34596928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2003801102572A Pending CN1764466A (en) | 2003-11-24 | 2003-11-24 | Application of Mango and its extracts in treating diabetes and improving its symptoms |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN1764466A (en) |
| AU (1) | AU2003304545A1 (en) |
| WO (1) | WO2005049057A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103550483A (en) * | 2013-11-01 | 2014-02-05 | 王娟 | Preparation method of medicine for treating 2-type diabetes |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1100504C (en) * | 1999-05-18 | 2003-02-05 | 潘世全 | Cassia sophera hypoglycemic thirst-quenching beverage and productive process |
-
2003
- 2003-11-24 CN CNA2003801102572A patent/CN1764466A/en active Pending
- 2003-11-24 AU AU2003304545A patent/AU2003304545A1/en not_active Abandoned
- 2003-11-24 WO PCT/CN2003/000995 patent/WO2005049057A1/en not_active Ceased
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103550483A (en) * | 2013-11-01 | 2014-02-05 | 王娟 | Preparation method of medicine for treating 2-type diabetes |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003304545A1 (en) | 2005-06-08 |
| WO2005049057A1 (en) | 2005-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109674958B (en) | Traditional Chinese medicine composition with effect of reducing uric acid and preparation method and application thereof | |
| CN111544550B (en) | Traditional Chinese medicine formula flora capsule, preparation method and application in preparation of medicine for treating type 2 diabetes | |
| CN115919963A (en) | Application of a kind of traditional Chinese medicine composition in the preparation of medicine for treating novel coronavirus infection | |
| CN104288344B (en) | Application of Pu' er tea extract in preparation of medicine or food for regulating intestinal flora and relaxing bowels | |
| CN1403138A (en) | Compound Chinese medicine prepn for treating urinary system infection and prostatitis and its prepn process | |
| CN108704058B (en) | Composition for treating pharyngitis and preparation method and application thereof | |
| CN104667175A (en) | Health care product with function of protecting alcoholic liver injury | |
| CN1764466A (en) | Application of Mango and its extracts in treating diabetes and improving its symptoms | |
| CN114748567B (en) | Hypoglycemic composition containing antrodia camphorata and preparation method and application thereof | |
| JP7157253B2 (en) | Chinese herbal composition for enema constipation, its preparation method and its use | |
| CN114259540A (en) | Traditional Chinese medicine composition for treating diabetes with syndrome of deficiency of both qi and yin and preparation method and application thereof | |
| CN101623443A (en) | Chinese medicinal composition for treating Qi-Yin deficiency symptom after radiotherapy and chemotherapy of malignant tumor and preparation method thereof | |
| Ajagun-Ogunleye et al. | Hypoglycemic and high dosage effects of bidens pilosa in type-1 diabetes mellitus | |
| CN116726105B (en) | Application of composition in preparation of medicines for treating metabolic-related fatty liver disease | |
| TWI698244B (en) | Use of a combination of small-molecule fucoidan and fucoxanthin for preparing a composition for improving non-alcoholic fatty liver | |
| CN114732889B (en) | Traditional Chinese medicine composition and traditional Chinese medicine oral preparation for treating phlegm turbidity and lung obstruction in acute attack stage of bronchial asthma | |
| CN112121056A (en) | The use of the composition of small molecule fucoidan and phycoxanthin for preparing the composition for improving non-alcoholic fatty liver | |
| CN119792394B (en) | A traditional Chinese medicine composition for lowering lipids, its preparation method and application | |
| CN104491637B (en) | It is a kind of to treat compound composite medicament of cough after common cold and preparation method and application | |
| CN110251633A (en) | A kind of pharmaceutical composition and preparation method thereof for treating Diabetes Complicated with Pulmonary Tuberculosis disease | |
| CN102430040A (en) | Medicine for treating diabetes | |
| WO2005048738A1 (en) | Use of cassia sophera and its aqueous extract for producing foods of reducing symptom of diabetic | |
| CN119488555A (en) | Use of Wulingdan pharmaceutical composition or its preparation in preparing medicine for preventing or treating non-alcoholic fatty hepatitis | |
| CN1562111A (en) | Application of the stem and leaf extract of Chimang in treating diabetes and improving its symptoms | |
| CN107510753B (en) | Traditional Chinese medicine composition for treating intractable hemoptysis and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |